491 related articles for article (PubMed ID: 32109716)
1. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.
Baraibar I; Mezquita L; Gil-Bazo I; Planchard D
Crit Rev Oncol Hematol; 2020 Apr; 148():102906. PubMed ID: 32109716
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Robichaux JP; Elamin YY; Tan Z; Carter BW; Zhang S; Liu S; Li S; Chen T; Poteete A; Estrada-Bernal A; Le AT; Truini A; Nilsson MB; Sun H; Roarty E; Goldberg SB; Brahmer JR; Altan M; Lu C; Papadimitrakopoulou V; Politi K; Doebele RC; Wong KK; Heymach JV
Nat Med; 2018 May; 24(5):638-646. PubMed ID: 29686424
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
5. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.
Passaro A; Prelaj A; Bonanno L; Tiseo M; Tuzi A; Proto C; Chiari R; Rocco D; Genova C; Sini C; Cortinovis D; Pilotto S; Landi L; Bennati C; Camerini A; Toschi L; Putzu C; Cerea G; Spitaleri G; Cappuzzo F; de Marinis F
Clin Lung Cancer; 2019 Mar; 20(2):e186-e194. PubMed ID: 30563752
[TBL] [Abstract][Full Text] [Related]
6. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
[TBL] [Abstract][Full Text] [Related]
7. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
[TBL] [Abstract][Full Text] [Related]
8. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
Oxnard GR; Lo PC; Nishino M; Dahlberg SE; Lindeman NI; Butaney M; Jackman DM; Johnson BE; Jänne PA
J Thorac Oncol; 2013 Feb; 8(2):179-84. PubMed ID: 23328547
[TBL] [Abstract][Full Text] [Related]
9. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.
Wang J; Li X; Xue X; Ou Q; Wu X; Liang Y; Wang X; You M; Shao YW; Zhang Z; Zhang S
Int J Cancer; 2019 Jun; 144(11):2677-2682. PubMed ID: 30255937
[TBL] [Abstract][Full Text] [Related]
12. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
13. NSCLC and HER2: between lights and shadows.
Ricciardi GR; Russo A; Franchina T; Ferraro G; Zanghì M; Picone A; Scimone A; Adamo V
J Thorac Oncol; 2014 Dec; 9(12):1750-62. PubMed ID: 25247338
[TBL] [Abstract][Full Text] [Related]
14. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
Bai Q; Wang J; Zhou X
Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
[TBL] [Abstract][Full Text] [Related]
15. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
Brazel D; Kroening G; Nagasaka M
BioDrugs; 2022 Nov; 36(6):717-729. PubMed ID: 36255589
[TBL] [Abstract][Full Text] [Related]
16. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Prelaj A; Bottiglieri A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Nichetti F; Manglaviti S; Occhipinti M; Labianca A; Ganzinelli M; Gallucci R; Zilembo N; Greco GF; Torri V; de Braud F; Garassino MC
Eur J Cancer; 2021 May; 149():235-248. PubMed ID: 33820681
[TBL] [Abstract][Full Text] [Related]
17. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
Nagasaka M; Singh V; Baca Y; Sukari A; Kim C; Mamdani H; Spira AI; Uprety D; Bepler G; Kim ES; Raez LE; Pai SG; Ikpeazu C; Oberley M; Feldman R; Xiu J; Korn WM; Wozniak AJ; Borghaei H; Liu SV
Clin Lung Cancer; 2022 Jan; 23(1):52-59. PubMed ID: 34801409
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
Lund-Iversen M; Kleinberg L; Fjellbirkeland L; Helland Å; Brustugun OT
J Thorac Oncol; 2012 Sep; 7(9):1471-3. PubMed ID: 22895145
[TBL] [Abstract][Full Text] [Related]
19. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract][Full Text] [Related]
20. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
